Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Financial Officer | August 16, 2022 | August 19, 2022 |
| Origin Materials, Inc.ORGN · Entity 52695 | Interim CFO | September 01, 2023 | September 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date August 16, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2032-08-16 | Direct | 255,313 |
Reported balance
After 2022-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-16 · Grant · Acquired 23,000 · Balance 255,313 F1: The option vests in two equal installments occurring on the first, and second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in two equal installments occurring on the first, and second anniversary of the date of grant.
Origin Materials, Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,650 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Grant · Acquired 125,000 · Balance 136,650 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of September 1, 2023, provided that Reporting Person continues to provide services to the Company through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of September 1, 2023, provided that Reporting Person continues to provide services to the Company through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 6, 2023 16:17 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048374 · doc4.xml · nonDerivative · entry 1 Haley Pamela · CIK 0001787373 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,650 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of September 1, 2023, provided that Reporting Person continues to provide services to the Company through each vesting date. Read SEC document |
| August 16, 2022 Filed Aug 19, 2022 00:56 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-22-046792 · doc4.xml · derivative · entry 1 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,313 Underlying: Common Stock · 23,000 shares Expires 2032-08-16 F1 · derivative.exercise_date: The option vests in two equal installments occurring on the first, and second anniversary of the date of grant. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:23 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $0.70 | $490.00 |
DisclosureSEC source: 0001209191-22-044269 · doc4.xml · nonDerivative · entry 1 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,088 F1 · shares: Reflects the purchase of 700 shares of the Issuer's common stock on 8/1/22 at a per share purchase price of $0.70 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock. F2 · balance_after: The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase period of August 4, 2020 to August 1, 2022. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 19:55 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-024267 · doc4.xml · derivative · entry 2 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,313 Underlying: Common Stock · 38,000 shares Expires 2032-04-11 F2 · derivative.exercise_date: The option vests in two equal installments occurring on the first, and second anniversary of the date of grant. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 19:55 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-024267 · doc4.xml · derivative · entry 1 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,313 Underlying: Common Stock · 50,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 23:43 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-005213 · doc4.xml · derivative · entry 2 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,313 Underlying: Common Stock · 85,000 shares Expires 2031-01-21 F2 · derivative.exercise_date: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service. Read SEC document |
| August 03, 2020 Filed Jan 25, 2021 23:43 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $3.16 | $2,212.00 |
DisclosureSEC source: 0001209191-21-005213 · doc4.xml · nonDerivative · entry 1 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638 F1 · shares: Reflects the purchase of 700 shares of the Issuer's common stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:14 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-20-006294 · doc4.xml · derivative · entry 2 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,588 Underlying: Common Stock · 40,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The option vests in 48 equal installments beginning February 29, 2020 and ending January 31, 2024. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:14 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $1.72 | $1,204.00 |
DisclosureSEC source: 0001209191-20-006294 · doc4.xml · nonDerivative · entry 1 Haley Pamela · CIK 0001787373 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,938 F1 · shares: Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/20 at a per share purchase price of $1.72 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.